Following antibody-directed binding to tumor target IgM isotype BCRs, the ADC is expected to be effectively internalized, followed by lysosomal degradation resulting in cleavage of the drug linker and intracellular release of the cytotoxic agent. This evidence concerns the gene CD40LG and neoplasm.